SCHEMBL5423453

SCHEMBL5423453

Cc1ccccc1S(=O)(=O)N1CCCC2(CCN(Cc3ccc(Oc4ccccc4)cc3)C2=O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP3A4 P08684 4/20 0.39
CYP2D6 P10635 4/20 0.39
TSHR P16473 3/20 0.39
USP2 O75604 2/20 0.39
CYP1A2 P05177 2/20 0.39
RIPK1 Q13546 1/20 0.38
HCRTR2 O43614 5/20 0.38
HCRTR1 O43613 3/20 0.38
DCTPP1 Q9H773 2/20 0.37
PKM P14618 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRK1 P41145 1/20 0.36
EPHX2 P34913 1/20 0.35
SCD O00767 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5429847 0.90 LIPE (0.43) NR3C1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL5428771 0.89 NR3C1 (0.39) NR3C1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL5425021 0.89 NR3C1 (0.45) NR3C1KMT2ACYP3A4CYP2D6TSHR
SCHEMBL5422204 0.88 CCR1 (0.39) NR3C1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL5427290 0.87 LMNA (0.50) NR3C1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL5422001 0.86 NR3C1 (0.43) NR3C1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL5429568 0.86 NR3C1 (0.43) NR3C1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL5427073 0.85 MCOLN3 (0.48) NR3C1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL5431821 0.85 LIPE (0.44) NR3C1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL5430005 0.85 MEN1 (0.40) NR3C1MEN1KMT2ACYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275990-A1 Heterocyclic Spiro Compound ONO PHARMACEUTICAL CO., LTD. 2007-11-29 US disclosed
EP-1683797-A1 HETEROCYCLIC SPIRO COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275990-A1 Heterocyclic Spiro Compound NR3C2, CBR1, CBR3 NR3C1 7/4885MEN1 995/4885KMT2A 2691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.